Balance Sheet

Accounts Payables Accumulated Depreciation Accumulated Expenses Assets Cash & Equivalents Common Equity Construction in Progress Convertible Debt Current Assets Current Deferred Revenue Current Leases Current Taxes Dividends payables Finished Goods Goodwill & Intangibles Intangibles Inventory Land & Improvements Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Shares Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Accured Receivables - Affiliates Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares

Daily Values

Growth Metrics

Others

Abvc Biopharma (ABVC) Work In Process (2018 - 2019)

Abvc Biopharma (ABVC) has disclosed Work In Process for 2 consecutive years, with $20676.0 as the latest value for Q4 2019.

For the quarter ending Q4 2019, Work In Process rose 2.14% year-over-year to $20676.0, compared with a TTM value of $20676.0 through Dec 2019, up 2.14%, and an annual FY2019 reading of $20676.0, up 2.14% over the prior year.
Work In Process was $20676.0 for Q4 2019 at Abvc Biopharma, up from $19937.0 in the prior quarter.
Across five years, Work In Process topped out at $20676.0 in Q4 2019 and bottomed at $19933.0 in Q2 2019.